CL2020000482A1 - Composición para la estimulación ovárica controlada. - Google Patents

Composición para la estimulación ovárica controlada.

Info

Publication number
CL2020000482A1
CL2020000482A1 CL2020000482A CL2020000482A CL2020000482A1 CL 2020000482 A1 CL2020000482 A1 CL 2020000482A1 CL 2020000482 A CL2020000482 A CL 2020000482A CL 2020000482 A CL2020000482 A CL 2020000482A CL 2020000482 A1 CL2020000482 A1 CL 2020000482A1
Authority
CL
Chile
Prior art keywords
composition
ovarian stimulation
controlled ovarian
fsh
controlled
Prior art date
Application number
CL2020000482A
Other languages
English (en)
Inventor
Saez Joan-Carles Arce
Lisbeth Helmgaard
Bjarke Mirner Klein
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of CL2020000482A1 publication Critical patent/CL2020000482A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

PREPARACIONES QUE INCLUYEN FSH, POR EJEMPLO, FSH RECOMBINANTE, PARA SU USO EN EL TRATAMIENTO DE LA INFERTILIDAD EN PACIENTES CON AMH ALTO, Y UN PESO CORPORAL BAJO.
CL2020000482A 2017-09-01 2020-02-27 Composición para la estimulación ovárica controlada. CL2020000482A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17189119 2017-09-01

Publications (1)

Publication Number Publication Date
CL2020000482A1 true CL2020000482A1 (es) 2020-06-26

Family

ID=59772482

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020000482A CL2020000482A1 (es) 2017-09-01 2020-02-27 Composición para la estimulación ovárica controlada.

Country Status (31)

Country Link
US (2) US11744879B2 (es)
EP (3) EP3973982B1 (es)
JP (2) JP6856819B2 (es)
KR (1) KR20200045543A (es)
CN (1) CN111050787A (es)
AR (1) AR112541A1 (es)
AU (1) AU2018326556B2 (es)
BR (1) BR112020003379A2 (es)
CA (1) CA3073624A1 (es)
CL (1) CL2020000482A1 (es)
DK (2) DK3675894T3 (es)
EA (1) EA202090480A1 (es)
ES (1) ES2904787T3 (es)
FI (1) FI3973982T3 (es)
HR (1) HRP20211802T1 (es)
HU (1) HUE056726T2 (es)
IL (1) IL272763B2 (es)
JO (1) JOP20200034A1 (es)
LT (2) LT3973982T (es)
MA (2) MA56224A (es)
MD (1) MD3675894T2 (es)
MX (2) MX2020002235A (es)
PH (1) PH12020500404A1 (es)
PL (1) PL3675894T3 (es)
PT (2) PT3973982T (es)
RS (1) RS62810B1 (es)
SG (1) SG11202003840QA (es)
SI (1) SI3675894T1 (es)
TW (1) TWI749255B (es)
UA (1) UA126869C2 (es)
WO (1) WO2019043143A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202237173A (zh) * 2020-12-09 2022-10-01 荷蘭商菲林公司 用於受控的卵巢刺激之組成物及方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1442748A1 (en) * 2000-01-27 2004-08-04 Applied Research Systems ARS Holding N.V. Use of FSH for treating infertility
US20040248784A1 (en) 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
WO2009036771A1 (es) * 2007-09-21 2009-03-26 Pharmabrand S.A. Composición de polisacáridos mucilaginosos, derivados de aloe barbadensis, en combinación con liposomas, procedimiento de obtención y uso de la misma como fotoprotectora, antiacné, regeneradora de la epidermis e hidratante
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
WO2011089602A2 (en) * 2010-01-21 2011-07-28 Ramot At Tel-Aviv University Ltd. Aloe-emodin derivatives and use thereof for the treatment of cancer
PL2621517T5 (pl) 2010-09-29 2024-01-29 Ferring B.V. Kompozycja do stosowania w leczeniu niepłodności
WO2012168680A1 (en) 2011-06-06 2012-12-13 Ferring B.V. Pharmaceutical preparation comprising recombinant fsh
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
KR20160144480A (ko) * 2014-04-18 2016-12-16 글리코토페 게엠베하 개선된 재조합 인간 난포-자극 호르몬을 이용한 조절된 난소 과다자극
JP7163027B2 (ja) 2015-02-26 2022-10-31 フェリング ベスローテン フェンノートシャップ 不妊症の処置方法
EP3662925B1 (en) * 2015-04-17 2021-04-07 Ferring B.V. Composition comprising fsh for treatment of infertility
JP6964519B2 (ja) 2015-04-24 2021-11-10 フェリング ベスローテン フェンノートシャップ ゴナドトロピンの製造方法
CN107709350A (zh) 2015-06-26 2018-02-16 辉凌公司 纯化和/或病毒灭活的方法
CN112088011A (zh) 2018-04-30 2020-12-15 辉凌公司 用于受控的卵巢刺激的组合物
TWI846743B (zh) 2018-10-17 2024-07-01 荷蘭商菲林公司 用於控制性卵巢刺激之組成物及方法

Also Published As

Publication number Publication date
EP3675894B1 (en) 2021-11-03
MX2024009224A (es) 2024-08-06
DK3675894T3 (da) 2022-01-24
MA50034B1 (fr) 2022-02-28
US20240024424A1 (en) 2024-01-25
PT3973982T (pt) 2024-09-16
BR112020003379A2 (pt) 2020-08-25
IL272763B2 (en) 2024-02-01
SG11202003840QA (en) 2020-05-28
EP3675894A1 (en) 2020-07-08
FI3973982T3 (fi) 2024-09-23
LT3973982T (lt) 2024-09-10
MX2020002235A (es) 2020-07-20
CA3073624A1 (en) 2019-03-07
JP2021046398A (ja) 2021-03-25
AR112541A1 (es) 2019-11-06
EA202090480A1 (ru) 2020-07-20
IL272763B1 (en) 2023-10-01
TWI749255B (zh) 2021-12-11
US20200197493A1 (en) 2020-06-25
PT3675894T (pt) 2022-01-25
WO2019043143A1 (en) 2019-03-07
DK3973982T3 (da) 2024-09-23
EP3973982A1 (en) 2022-03-30
HUE056726T2 (hu) 2022-03-28
MD3675894T2 (ro) 2022-03-31
MA50034A (fr) 2021-05-12
ES2904787T3 (es) 2022-04-06
EP4427806A2 (en) 2024-09-11
EP3973982B1 (en) 2024-07-31
IL272763A (en) 2020-04-30
CN111050787A (zh) 2020-04-21
PH12020500404A1 (en) 2021-03-01
JOP20200034A1 (ar) 2020-02-13
HRP20211802T1 (hr) 2022-03-04
JP6856819B2 (ja) 2021-04-14
UA126869C2 (uk) 2023-02-15
LT3675894T (lt) 2021-12-10
PL3675894T3 (pl) 2022-02-21
MA56224A (fr) 2022-04-20
AU2018326556B2 (en) 2024-09-26
US11744879B2 (en) 2023-09-05
KR20200045543A (ko) 2020-05-04
TW201919687A (zh) 2019-06-01
RS62810B1 (sr) 2022-02-28
JP2020528071A (ja) 2020-09-17
SI3675894T1 (sl) 2022-01-31
EP4427806A3 (en) 2024-10-09
JP7373479B2 (ja) 2023-11-02
AU2018326556A1 (en) 2020-03-05

Similar Documents

Publication Publication Date Title
DOP2017000097A (es) Composiciones y métodos de uso para tratar trastornos metabólicos
CO2018004315A2 (es) Conjugados de 2-amino-pirrolo [3,2] pirimidina con anticuerpos anti-her-2
CO2021001912A2 (es) Composiciones anti-cd112r y métodos
ECSP18096095A (es) Anticuerpos a la alfa-sinucleína y usos de los mismos
CL2018002012A1 (es) Derivados de maitansinoide, conjugados de los mismos y métodos de uso.
DOP2019000191A (es) Anticuerpos anti-tgf-beta y su uso
CL2017000201A1 (es) Composiciones y métodos de uso para tratar trastornos metabólicos
CL2018003141A1 (es) Polipéptidos de fusión cd40l-fc y sus métodos de uso.
BR112015018104A2 (pt) polipeptídeos de gdf15 modificados, seu uso, composições compreendendo os mesmos e recipiente estéril compreendendo as referidas composições
MX2020004801A (es) Polipeptidos de fusion biespecificos y sus metodos de uso.
EP4218809A3 (en) Combination therapy using inhibitors of human growth and differentiation factor 15 (gdf-15) and immune checkpoint blockers
CL2016002482A1 (es) Compuestos de azol sustituidos con amida como inhibidores de tnks1 y/o tnks2.
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
MX2020003563A (es) Anticuerpo anti-pacap.
CL2021000129A1 (es) Apirasas solubilizadas, métodos y usos
CL2020000812A1 (es) Semaglutida en la terapia médica.
MX2019011297A (es) Complejo de analogo de insulina con afinidad reducida por el receptor de insulina y uso del mismo.
ES2721935T3 (es) Anticuerpos anti-BAG3 para uso terapéutico
BR112019004906A2 (pt) combinação incluindo abx196 para o tratamento de câncer
AR109279A1 (es) Anticuerpos anti plazomicina y métodos de uso de los mismos
AR106981A1 (es) Una composición antimicrobiana
CL2020000482A1 (es) Composición para la estimulación ovárica controlada.
CO2021005872A2 (es) Composiciones y métodos para la estimulación ovárica controlada
AR105728A1 (es) Lisobactina para su uso en el tratamiento de la mastitis bovina